<DOC>
	<DOCNO>NCT00489229</DOCNO>
	<brief_summary>The aim examine whether pharmacological intervention thiazolidinedione angiotensin convert enzyme ( ACE ) inhibitor reverse pre-clinical vasculopathy newly diagnose diabetic IGT individual .</brief_summary>
	<brief_title>To Investigate Effect Rosiglitazone Ramipril Pre-clinical Vasculopathy Diabetes IGT Patients</brief_title>
	<detailed_description>The burden diabetic vasculopathy global population enormous ever grow . Besides well-known microvascular complication type 2 diabetes ( T2DM ) , grow epidemic macrovascular complication . People T2DM high risk death cardiovascular ( CV ) diseases person without diabetes . Like diabetes , impair glucose tolerance ( IGT ) individual also associate risk develop macrovascular complication . This call early detection intervention patient T2DM well IGT , delay progression IGT T2DM also treat early macrovascular disease group . The traditional therapeutic approach T2DM emphasise glycaemic control , limit microvascular disease lack establish benefit macrovascular disease . Type 2 diabetes metabolic disorder characterise dyslipidaemia , hypertension , hypercoagulability addition hyperglycaemia hyperinsulinaemia . Each abnormality play important role diabetic vasculopathy provide target therapy . Understanding mechanisms diabetic vasculopathy institute therapy guide emerging evidence would improve outcome patient T2DM IGT . In recent year , special attention devote thiazolidinediones ( TZDs ) angiotensin convert enzyme ( ACE ) inhibitor TRIPOD study demonstrate troglitazone may reduce rate progression diabetes woman diagnose gestational diabetes HOPE Study show ramipril may delay onset diabetes . The TZDs novel insulin-sensitising antidiabetic agent , also vasculoprotective property . Rosiglitazone , one member TZD family , improve insulin sensitivity may beta cell cytoprotective effect . The ACE inhibitor reduce microvascular macrovascular complication diabetes appear improve insulin sensitivity glucose metabolism . Ramipril , ACE inhibitor , direct effect renin-angiotensin-kallikrein system may play important role prevention diabetes effect beta cell vascular metabolic effect muscle may amplify effect insulin . Previous study show newly diagnose untreated T2DM/IGT hypertensive Malay patient early manifestation preclinical vasculopathy potentially increase risk development macrovascular disease . The aim study investigate whether pharmacological intervention rosiglitazone ramipril reverse pre-clinical vasculopathy newly diagnose untreated T2DM IGT patient .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Newly diagnose untreated T2DM patient Newly diagnose untreated IGT patient Normoglycaemic individual Age : 3065 year Blood Pressure &lt; 140/90 mmHg . Patients T2DM Hypertension ( &gt; 140/90 mmHg ) Microvascular and/or macrovascular complication diabetes Severe hyperlipidaemia ( &gt; 7.8 mmol/L ) Smokers Obese people ( BMI &gt; 30 Kg/m2 )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Rosiglitazone</keyword>
	<keyword>Ramipril</keyword>
	<keyword>Impaired glucose tolerance</keyword>
	<keyword>Arterial stiffness</keyword>
	<keyword>Diabetic vasculopathy</keyword>
</DOC>